Compare Enact Holdings Inc (ACT) vs Baxter International Inc (BAX) Price & Performance

ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.

Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.

Baxter International (BAX) trades at $22.86, up 0.93% today, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains weak with a negative net income margin of -9.7% and ROE of -16.73%. Cash flow trends indicate operational challenges, with net cash flow negative in recent periods. Recent news highlights sustainability initiatives and strategic partnerships, supporting a turnaround narrative amid ongoing financial restructuring.

Outlook: BAX presents a mixed opportunity with analyst consensus leaning Hold (52.77%) amid valuation concerns (P/E 87.85) and persistent losses. Key risks include high debt, margin pressure, and execution hurdles in stabilizing the business. Upside potential exists if operational improvements and AI integration drive sustained earnings recovery, but investors should weigh the high volatility and competitive pressures in the medtech sector.